Annual report pursuant to Section 13 and 15(d)

Royalty Purchase Agreements - Aronora (Details)

v3.20.1
Royalty Purchase Agreements - Aronora (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Apr. 07, 2019
USD ($)
item
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Long-term royalty receivables     $ 34,375 $ 15,000
Impairment of long-term royalty receivable     0 0
Payments to acquire milestones and royalties     19,300 15,000
Proceeds from issuance of long-term debt     9,500 $ 7,500
Aronora | Non-Bayer Products        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Number of drug candidates | item 2      
Royalty Purchase Agreement | Aronora        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Number of drug candidates | item 5      
Non-royalties to be received (as a percent) 10.00%      
Future non-royalty payments to be received (as a percent) 5.00%      
Multiplier for cumulative amount of consideration paid | item 2      
Upfront payment $ 6,000      
Threshold amount of cumulative royalties on net sales per product 250,000      
Long-term royalty receivables 9,000      
Contingent consideration liability 3,000      
Payments of contingent consideration   $ 3,000    
Impairment of long-term royalty receivable     $ 0  
Aggregate milestones payments per product 85,000      
Royalty Purchase Agreement | Aronora | Silicon Valley Bank Loan Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Upfront payment $ 3,000      
Royalty Purchase Agreement | Aronora | Bayer Products        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Number of drug candidates | item 3      
Number of drug candidates subject to exclusive license option | item 1      
Royalties on net sales of products (as a percent) 100.00%      
Non-royalties to be received (as a percent) 10.00%      
Contingent future cash payment for each product $ 1,000      
Potential future cash payments $ 3,000      
Royalty Purchase Agreement | Aronora | Non-Bayer Products        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Non-royalties to be received (as a percent) 10.00%